Overcoming Acquired and Native Macrolide Resistance with Bicarbonate

被引:24
作者
Farha, Maya A. [1 ,2 ]
MacNair, Craig R. [1 ,2 ]
Carfrae, Lindsey A. [1 ,2 ]
El Zahed, Sara S. [1 ,2 ]
Ellis, Michael J. [1 ,2 ]
Tran, Hiu-Ki R. [1 ,2 ]
McArthur, Andrew G. [1 ,2 ]
Brown, Eric D. [1 ,2 ]
机构
[1] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada
[2] McMaster Univ, Michael G DeGroote Inst Infect Dis Res, Hamilton, ON L8N 3Z5, Canada
基金
加拿大健康研究院;
关键词
Macrolide antibiotics; bicarbonate; macrolide resistance; drug uptake; mechanism of action; mouse models of infection; INDUCIBLE CLINDAMYCIN RESISTANCE; PSEUDOMONAS-AERUGINOSA; ANTIBIOTIC-RESISTANCE; PERMEABILITY BARRIER; ESCHERICHIA-COLI; AZITHROMYCIN; ERYTHROMYCIN; CLARITHROMYCIN; SUSCEPTIBILITY; STREPTOGRAMIN;
D O I
10.1021/acsinfecdis.0c00340
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The growing challenge of microbial resistance - Bicarbonate emphasizes the importance of new antibiotics or reviving strategies for the use of old ones. Macrolide antibiotics are potent bacterial protein synthesis inhibitors with a formidable capacity to treat life-threatening bacterial infections; however, acquired and intrinsic resistance limits their clinical application. In the work presented here, we reveal that bicarbonate is a potent enhancer of the activity of macrolide antibiotics that overcomes both acquired and intrinsic resistance mechanisms. With a focus on azithromycin, a highly prescribed macrolide antibiotic, and using clinically relevant pathogens, we show that physiological concentrations of bicarbonate overcome drug resistance by increasing the intra-cellular concentration of azithromycin. We demonstrate the potential of bicarbonate as a formulation additive for topical use of azithromycin in treating a murine wound infection caused by Pseudomonas aeruginosa. Further, using a systemic murine model of methicillin-resistant Staphylococcus aureus (MRSA) infection, we demonstrate the potential role of physiological bicarbonate, naturally abundant in the host, to enhance the activity of azithromycin against macrolide-resistant MRSA. In all, our findings suggest that macrolide resistance, observed in the clinical microbiology laboratory using standard culturing techniques, is a poor predictor of efficacy in the clinic and that observed resistance should not necessarily hamper the use of macrolides. Whether as a formulation additive for topical use or as a natural component of host tissues, bicarbonate is a powerful potentiator of macrolides with the capacity to overcome drug resistance in life-threatening bacterial infections.
引用
收藏
页码:2709 / 2718
页数:10
相关论文
共 50 条
[1]   CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database [J].
Alcock, Brian P. ;
Raphenya, Amogelang R. ;
Lau, Tammy T. Y. ;
Tsang, Kara K. ;
Bouchard, Megane ;
Edalatmand, Arman ;
Huynh, William ;
Nguyen, Anna-Lisa, V ;
Cheng, Annie A. ;
Liu, Sihan ;
Min, Sally Y. ;
Miroshnichenko, Anatoly ;
Tran, Hiu-Ki ;
Werfalli, Rafik E. ;
Nasir, Jalees A. ;
Oloni, Martins ;
Speicher, David J. ;
Florescu, Alexandra ;
Singh, Bhavya ;
Faltyn, Mateusz ;
Hernandez-Koutoucheva, Anastasia ;
Sharma, Arjun N. ;
Bordeleau, Emily ;
Pawlowski, Andrew C. ;
Zubyk, Haley L. ;
Dooley, Damion ;
Griffiths, Emma ;
Maguire, Finlay ;
Winsor, Geoff L. ;
Beiko, Robert G. ;
Brinkman, Fiona S. L. ;
Hsiao, William W. L. ;
Domselaar, Gary, V ;
McArthur, Andrew G. .
NUCLEIC ACIDS RESEARCH, 2020, 48 (D1) :D517-D525
[2]   Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis [J].
Amsden, GW ;
Baird, IM ;
Simon, S ;
Treadway, G .
CHEST, 2003, 123 (03) :772-777
[3]   Pneumococcal macrolide resistance - myth or reality? [J].
Amsden, GW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (01) :1-6
[4]   INVITRO [H-3] ERYTHROMYCIN BINDING TO STAPHYLOCOCCUS-AUREUS [J].
BARRE, J ;
FOURNET, MP ;
ZINI, R ;
DEFORGES, L ;
DUVAL, J ;
TILLEMENT, JP .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (06) :1001-1004
[5]   Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin [J].
Bosnar, M ;
Kelneric, Z ;
Munic, V ;
Erakovic, V ;
Parnham, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2372-2377
[6]   Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review [J].
Cai, Yun ;
Chai, Dong ;
Wang, Rui ;
Bai, Nan ;
Liang, Bei-Bei ;
Liu, Youning .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (05) :968-978
[7]  
Chancey ST, 2012, FUTURE MICROBIOL, V7, P959, DOI [10.2217/FMB.12.63, 10.2217/fmb.12.63]
[8]   The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia [J].
Cilloniz, Catia ;
Albert, Richard K. ;
Liapikou, Adamanthia ;
Gabarrus, Albert ;
Rangel, Ernesto ;
Bello, Salvador ;
Marco, Francesc ;
Mensa, Josep ;
Torres, Antoni .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191 (11) :1265-1272
[9]   Origins and Evolution of Antibiotic Resistance [J].
Davies, Julian ;
Davies, Dorothy .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2010, 74 (03) :417-+
[10]   Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada [J].
De Azavedo, JCS ;
Yeung, RH ;
Bast, DJ ;
Duncan, CL ;
Borgia, SB ;
Low, DE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2144-2147